220394-85-4

Upstream product

• 103-82-2 phenylacetic acid 
• 1575-70-8 2-phenyl-pent-4-enoic acid 
• 76403-12-8 2-Phenyl-4-pentenoyl chloride 
• 169466-57-3 N-methyl-(2-phenylpent-4-enyl)amine 
• 169466-55-1 (S)-2-phenylpent-4-enoic acid, N-methyl amide 
• 220394-84-3 (R,S)-N-(2-Phenylpent-4-en-1-yl)-N-methylbenzene-sulfonamide 
• 7529-22-8 4-methylmorpholine N-oxide 
• 5292-53-5 diethyl benzalmalonate 
• 14025-83-3 3-cyano-3-phenylpropanoic acid ethyl ester 
• 1262786-56-0 ethyl 3-phenyl-4-[(phenylsulfonyl)amino]butanoate 
• 1262786-57-1 N-(4-hydroxy-2-phenylbutyl)benzenesulfonamide 
• 1262786-58-2 N-(4-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-2-phenylbutyl)benzenesulfonamide 
• 1262786-59-3 N-(4-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-2-phenylbutyl)-N-methylbenzenesulfonamide 
• 1262786-60-6 N-(4-hydroxy-2-phenylbutyl)-N-methylbenzenesulfonamide 

Downstream Products

• 220394-86-5 (R,S)-N-[2-Phenyl-4-(4-phenylpiperidin-1-yl)but-1-yl]-N-methylbenzenesulfonamide hydrochloride salt 
• 1262786-22-0 N-methyl-N-{4-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenylbutyl}benzenesulfonamide 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS

The present invention relates to compounds of Formula (I) and (Ia) useful in the treatment of CCR5-related diseases and disorders, for example, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficien

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: Structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes

(2S)-2-(3,4-Dichlorophenyl)-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-[spiro(2 ,3-dihydrobenzthiophene-3,4′-piperidin-1′yl)]butane S-oxide (3) has been identified as a potent CCR5 antagonist lead structure having an IC50 = 35 nM. Herein, we describe the structure-activity relationship studies directed toward the requirement for and optimization of the C-2 phenyl fragment. The phenyl was found to be important for CCR5 antagonism and substitution was limited to small moieties at the 3-position (13 and 16: X = H, 3-F, 3-Cl, 3-Me).

CYCLIC AMINE MODULATIONS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to cyclic amines of the formula I: STR1 (wherein R 1, R 2, R 3, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.